Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

The liver is a highly dynamic metabolic organ that plays critical roles in plasma protein
synthesis, gluconeogenesis and glycogen storage, cholesterol metabolism and bile acid …

High levels of cholesterol are generally considered to be associated with atherosclerosis. In
the past two decades, however, a number of studies have shown that excess cholesterol …

Nonalcoholic fatty liver disease is the most prevalent liver disease worldwide, affecting 20%–
25% of the adult population. In 25% of patients, nonalcoholic fatty liver disease progresses …

Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …

Glutathione (GSH), a tripeptide particularly concentrated in the liver, is the most important
thiol reducing agent involved in the modulation of redox processes. It has also been …

The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and NAFLD‐related
cirrhosis in the United States and globally highlights the need to better understand the …

Nonalcoholic fatty liver disease (NAFLD) progresses to nonalcoholic steatohepatitis (NASH)
in response to elevated endoplasmic reticulum (ER) stress. Whereas the onset of simple …

Lipids encompass a wide variety of molecules such as fatty acids, sterols, phospholipids,
and triglycerides. These molecules represent a highly efficient energy resource and can act …